


# FUNDACIÓN RAMÓN ARECES

Simposio Internacional  
**Investigación y desarrollo de nuevas vacunas contra la  
tuberculosis**

*Internacional Symposium*  
***Research and development of new tuberculosis vaccines***

Zaragoza, 3 y 4 de junio de 2010  
*June 3-4, 2010*



**CURRÍCULUM VITAE**

- 1.-[Douglas Young](#)
- 2.-[Ann Rawkins](#)
- 3.-[Pere Joan Cardona](#)
- 4.-[Paul-Henri Lambert](#)
- 5.-[Hazel Dockrell](#)
- 6.-[Tom Ottenhoff](#)
- 7.-[Stefan Kaufmann](#)
- 8.-[Giulano Gargioni](#)
- 9.-[Emma Huitric](#)
- 10.-[Hannu Laang](#)
- 11.-[Jan Gheuens](#)
- 12.-[Jelle Thole](#)
- 13.-[Carlos Martín](#)

## **Currículum Vitae Douglas Young**



**Douglas Young is the Fleming Professor of Medical Microbiology at Imperial College London** and Head of the Division of Mycobacterial Research at the MRC National Institute for Medical Research UK, where he leads a research team that focuses on understanding molecular mechanisms of mycobacterial pathogenesis.

After completing degrees in biochemistry from the University of Edinburgh and the University of Oxford in 1978, Prof Young was introduced to mycobacterial research during a two-year post-doctoral fellowship studying leprosy in Mumbai, India. Over the last three decades, he has worked on the microbiology and immunology of tuberculosis with appointments at the University of Washington in Seattle and with the Medical Research Council and Imperial College in London.

From 1992 to 1998, Prof Young chaired the Immunology of Mycobacteria (IMMYC) Steering Committee at the World Health Organisation, and was chair of the New Vaccines Working Group of the Stop TB Partnership from 2003 to 2006. Prof Young advises the UK Department of the Environment, Food and Rural Affairs on the use of vaccines to control bovine TB and is a member of the Board of Directors of the Aeras Global TB Vaccine Foundation.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae Ann Rawkins**



**Dr. Ann Rawkins nee Williams** is currently a **Scientific Leader at the HPA Centre for Emergency Preparedness and Response, UK**. Her role is to provide scientific direction to the TB research programme, which aims to identify and develop vaccine and/or therapeutic targets and evaluate these in aerosol-challenge in-vivo models. The vaccine evaluation team, which Dr Rawkins has led for the past 15 years has been a key component of the European effort to develop an improved TB vaccine.

Prior to her TB studies she worked at the same site in the Centre for Applied Microbiology and Research studying Salmonella infection in chickens for 4 years and before that conducted her PhD studies on the pathogenic mechanisms of Legionnaires' disease.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae Pere Joan Cardona**



**Dr. Pere-Joan Cardona** is a biomedical researcher of the **Germans Trias i Pujol Biomedical Research Foundation** attached to the Spanish Health Department (Fondo de Investigaciones Sanitarias –FIS-). He is also Associate Professor at the Universitat Autònoma de Barcelona (UAB). He was qualified as MD at the UAB in 1992, completed his internal ship in Clinical Microbiology at the Germans Trias i Pujol University Hospital in 1997.

Dr. Cardona is a member of ASM, IUATLD, SEPAR (Spanish Society of Pneumology and Thoracic Surgery), SEIMC (Spanish Society of Clinical Microbiology and Infectious Diseases) and SECAL (Spanish Society of Laboratory Animal Sciences). He was qualified as Level D researcher by the FELASA in 2006. He obtained a PhD in 1999. His research was focused on infection models in laboratory animals and studies of TB diagnosis to search for serological methods of diagnosis.

He has been attached as Collaborator and Main Researcher in different FIS, SEPAR, FEPAR, SEIMC, FEDER and MEC. Nowadays he also collaborates in big European (TBVAC) and world (Grand Challenge #12) research linked to the study of new prophylactic and therapeutic vaccines against *M. tuberculosis* infection. He has published 32 articles in international peer-reviewed journals.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae Paul-Henri Lambert**

### **Prof. Paul-Henri Lambert**



**TBVI Steering Committee chairman Paul-Henri Lambert**, MD, is a retired professor associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is particularly interested in vaccination strategies and risk evaluation. Prof. Lambert is directing the International Advanced Course of Vaccinology (ADVAC) organised under the auspices of the Fondation Mérieux and University of Geneva.

Prof. Lambert is also chairing the steering committee of the European Consortium for the development of new tuberculosis vaccines (TBVAC), and the vaccine committee of the International Association for Biologicals (IANS) and, until December 2008, chaired the WHO Global Advisory Committee for Vaccine Safety.

A native of Belgium, Prof. Lambert was boarded in Internal Medicine (University of Liege). In 1966, he joined Frank Dixon at Scripps Clinic and Research Foundation, La Jolla, California, for immunopathology training. He then moved to University of Geneva Medical School as head of a research unit (1970), becoming professor in the Department of Medicine (1974) and affiliated in the Department of Pathology (1984).

Prof. Lambert led the Immunology Research and Training Programme of the World Health Organization (WHO) and the WHO-associated research laboratories at Universities of Geneva and Lausanne (1975-1987). During this period his research activities lead him to decipher immunological mechanisms involved in autoimmune and immune complex-mediated diseases and in the pathogenesis of malaria. He then became involved in the development of new strategies to optimise vaccine immunogenicity. Prof. Lambert was appointed as chief Microbiology and Immunology at the World Health Organization (1987) and Chief, Vaccine Research and Development, WHO Global Programme for Vaccines and Immunisation (1994). As such he was deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries.

Lambert is author or co-author of more than 400 publications, member of several international scientific boards, foreign member of the Royal Academy of Medicine in Belgium and Fellow of the American Association for the Advancement of Science.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae Hazel Dockrell**



**Professor Hazel M. Dockrell** is Professor of Immunology at the **London School of Hygiene and Tropical Medicine**. She obtained a BA (Mod) in Microbiology at Trinity College, Dublin followed by a PhD in autoimmunity at the Royal Dental Hospital of London. She then worked at the Middlesex Hospital Medical School, London on the immunology of malaria until she joined the London School of Hygiene & Tropical Medicine in 1985.

Her current research interests include the immunology of mycobacterial diseases (tuberculosis and leprosy) and the development of correlates of protection that could be used in new TB vaccine or drug trials. Recent studies have included comparisons of immunity induced by BCG vaccination in the UK and Malawi. A particular interest has been the development of field-friendly assays that could be used to assess immunity in field conditions.

Prof Dockrell has collaborated with many overseas institutions including in Pakistan, Mexico, Portugal and The Gambia, and most recently her BCG vaccination studies have been based at the Karonga Prevention Study in Malawi. Her group is currently funded by various EU consortia, Bill & Melinda Gates Foundation, and EDCTP. In 2008 she became Deputy Director (Research), a part-time role concerned with research strategy and governance, and with oversight of the research and capacity building projects run by LSHTM staff overseas.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae Tom Ottenhoff**



**Prof. Tom H. M. Ottenhoff** (MD 1982, PhD 1986) from **Leiden University Medical Centre (LUMC)** has longstanding expertise in the fields of immunology, immunopathology, immunogenetics and cell biology of infectious diseases caused by mycobacteria, particularly leprosy and tuberculosis. He has made several contributions to the characterisation of the human T cell response against mycobacterial pathogens, including the identification of novel antigens and epitopes, and the cellular and molecular mechanisms that control immunity to mycobacteria.

Current research projects include: (i) the development of effective and novel vaccines against tuberculosis, based on fundamental insights into the immunology and cell biology of host/pathogen interactions in tuberculosis, (ii) the genetic basis of susceptibility to disease and disease manifestations of infections caused by intracellular bacterial pathogens, and (iii) the immunopathogenesis of tissue damage in anti-mycobacterial immunity. The Ottenhoff laboratory has extensive knowledge and experience with intracellular bacteria, in regards to mycobacterial species as well as Salmonella.

Research has focused on both the innate as well as the adaptive immune response to bacterial infection with particular focus on the host mechanisms that are essential in regulating such infections. Prof. Ottenhoff has an extensive list of publications in peer-reviewed journals.

[VOLVER / TO RETURN ↑](#)



## **Currículum Vitae de Stefan Kaufmann**



**Prof. Dr. Dr. h.c. Stefan H. E. Kaufmann** is (founding) director of the **Department of Immunology of the Max Planck Institute for Infection Biology in Berlin**, Germany. He is professor for microbiology and immunology at the Charité, Humboldt University, Berlin, and honorary professor at the University Clinics Benjamin Franklin, Free University Berlin.

Prof. Kaufmann is former president and honorary member of the German Society for Immunology, former president of the European Federation of Immunological Societies (EFIS) and vice president of the International Union of Immunological Societies (IUIS).

Born 1948 in Ludwigshafen am Rhein, Prof. Kaufmann studied biology at the Johannes Gutenberg University of Mainz, 1977 PhD (highest degree, summa cum laude). He was professor for medical microbiology and immunology (1987- 1991) and full professor for immunology at the University of Ulm (1991-1998). His scientific interests are: immunity to bacterial pathogens with emphasis on tuberculosis and rational vaccine design.

Prof. Kaufmann initiated the Day of Immunology to raise public awareness in immunology. He received numerous scientific awards. He is Doctor Honoris Causa from Université de la Méditerranée, Aix-Marseille II, and coordinator of several international and interdisciplinary projects including Grand Challenge 6 by the Bill and Melinda Gates Foundation.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae de Giulano Gargioni**

**Dr. Giuliano Gargioni** is a **Team Leader, Partnering and Social Mobilisation of STOP-TB**. He was born in Milan, Italy, in 1959. He is married with five children.

He holds a degree in Medicine and Surgery and a specialization in Tuberculosis and Lung Diseases.

In 1986 he left Italy and began working in Uganda. From 1986 to 1989 we worked as a medical officer and head of the Medicine general ward and the TB ward in the district government hospital in Kitgum, in war-stricken Northern Uganda.

From 1989 to 1993 he held the position of District Medical Officer in the same district, managing all public health programs (including HIV/AIDS and TB control) and several community-based health care initiatives.

From 1994 to 2002 he worked full time as senior adviser to the National TB & Leprosy Programme at the Ministry of Health in Kampala, initially as an expert of the Ministry of Foreign Affairs of Italy and, from 1998, as a WHO staff, serving at the same time on short missions to other Eastern and Southern African countries.

At the end of 2002 he was posted to the WHO Stop TB Department in Geneva, where he has worked as focal point for TB control in Africa and for initiatives of community-based TB care. He currently works as leader of the Partnering and Social Mobilization Team within the Stop TB Partnership Secretariat, dealing with the promotion in countries of national partnerships to Stop TB.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae Emma Huitric**

**Dr. Emma Huitric** is the **Scientific Officer for Tuberculosis at the European Centre for Disease Prevention and Control (ECDC)**. She has a background in anti-TB drugs and resistance-development to these, having based her PhD-studies in this field of research. Currently at ECDC, Emma's main focus of work is new tools for tuberculosis; an area which comprises new drugs, diagnostic tools and vaccines. Within this field and under the ECDC mandate, one of the key functions within the TB programme is to provide EU-Member States with the latest, most up-to-date scientific evidence as a support for developing and improving national TB programmes. For example, the TB programme is currently developing EU-adapted guidance on the use of Interferon-Gamma Release Assays (IGRAs) for the diagnosis of latent TB infection and active TB disease. Furthermore, the ECDC recently formed a European Reference Laboratory Network for TB (ERLN-TB), represented by all MS, which will play a further important role in assuring the optimal introduction of new tools for TB as they become available. Within the area of vaccination, the ECDC has focussed on the practices of BCG-vaccination having developed a model for determining BCG vaccination strategies, which it provided to countries in the process of reassessing their BCG vaccination strategies. The ECDC TB programme is represented in several international initiatives, as it is well known that TB control and elimination cannot be attained without a global effort. This includes the StopTBP Partnership sub group Introducing New Approaches and Tools for TB (INAT), and the WHO Global Laboratory Initiative (GLI).

[VOLVER / TO RETURN ↑](#)

## **Currículum Vítae de Hannu Laang**



**Hannu Lång** is a **Scientific Officer working in the Unit of Infectious Diseases of the Health Directorate of DG Research of the European Commission**. His current responsibilities consist of Tuberculosis research policy, planning of activities in the field of Tuberculosis research and managing the portfolio of FP6 and FP7 funded research projects. He is an observer in the Board of Trustees of the Tuberculosis Vaccine Initiative (TBVI), member of the task force of the WHO StopTB Tuberculosis research Movement and representative of the Commission in the Stakeholders Association of TB Alliance.

Before joining the European Commission he was doing research and teaching Molecular Microbiology as Professor of Microbiology at the University of Helsinki. He received his Ph.D. in Molecular Genetics from the Swedish University of Agricultural Sciences. Before joining the European Commission in 2005 he had a long career in science in Finland, Sweden and Australia, focusing on understanding molecular mechanisms of bacterial pathogenesis. He was awarded docentship at the University of Helsinki in 2002.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae de Jan Gheuens**



**Dr. Jan Gheuens** joined the [Bill & Melinda Gates Foundation](#) in 2007 as a Senior Program Officer for the Tuberculosis program. In this role, he focuses on the development of new TB diagnostics, vaccines and drugs.

Dr. Gheuens came to the BMGF from Amgen, where he was Vice President, Global Development Operations, and R&D Japan. In this capacity, he enhanced Amgen's global clinical trial capability, added regional competencies in Eastern Europe, Latin America and Asia, and managed a team accountable for the execution of clinical trials in over 35 countries.

Prior to his 6 years at Amgen, Dr. Gheuens spent 10 years at Johnson and Johnson. He took on various product development, clinical development and medical affairs roles of increasing responsibility at Janssen Research Foundation and Janssen Pharmaceutica US, culminating as Vice President Medical Affairs.

Before joining the biopharmaceutical sector he was trained as a Neurologist in his native Belgium, did a postdoctoral fellowship in the NIH Intramural Program, was awarded a Ph.D. in Neuroimmunology, and served for 7 years on the faculty at the University Hospital of Antwerp.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae de Jelle Thole**



Dr. Jelle Thole, graduated in medical biology in 1984, PhD in Medicine in 1988, has more than fifteen years of experience in molecular, and immunological research on mycobacteria (> 70 peer reviewed publications). Since 2004, he acted as coordinator of TBVAC, a consortium of 33 European and African laboratories that work together to develop and clinically test new vaccines against tuberculosis (supported by the EC Sixth Frame work). The success of this project has been the basis for the recent establishment of a foundation called TuBerculosis Vaccine Initiative (TBVI) aiming to sustain and extend European efforts for tuberculosis vaccine development.

[VOLVER / TO RETURN ↑](#)

## **Currículum Vitae de Carlos Martín**



**Dr. Carlos Martin is Professor of Microbiology at the Faculty of Medicine at University of Zaragoza** and heads the Mycobacteria Genetics Group since 1992, working in the research and development of new live vaccines against tuberculosis. He currently works in diverse collaborative research project funded by European Union in tuberculosis between research groups of Europe, Asia and Latin America.

Dr. Martin came to the University of Zaragoza from Pasteur Institute in Paris, where he was permanent researcher. Prior to his five years at Pasteur, he spent two years as postdoctoral fellow studying the mechanisms of resistance and transposition in bacteria in the Department of Biochemistry and Molecular Biology, University of Cantabria.

Dr. Martin is a Medical Doctor and has a PhD in Microbiology and Biochemistry. He is founding Member of the Tuberculosis Network of Latin America and the Caribbean sponsored by the University of United Nations (1995). In 2006 he received the Sustainable Development Award by “Fundación Ecología y Desarrollo”.

[VOLVER / TO RETURN ↑](#)